Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Is Pfizer Stock a Buy Now?
08:00am, Friday, 24'th Nov 2023
With declining revenue and earnings, Pfizer's business doesn't seem to be doing well. However, its long-term prospects look attractive thanks to shrewd decisions and investments.
How To Build A Dividend Portfolio Allocating $100,000 Among November's Top 20 Dividend Companies
06:00pm, Thursday, 23'rd Nov 2023
I will show you how you can build a dividend portfolio by allocating $100,000 among November's top 20 dividend companies as well as one ETF. I will conduct a deep risk analysis to demonstrate the redu
2 Stocks You'll Be Grateful You Bought at These Bargain Prices
05:00am, Wednesday, 22'nd Nov 2023
A bargain stock bought today could offer great rewards over time. Right now, some industry heavyweights are on sale -- and you'll want to snap them up before they take off.
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
10:00am, Tuesday, 21'st Nov 2023
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice P
Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips
07:10am, Tuesday, 21'st Nov 2023
It's always and forever a market of stocks, not a stock market. The Nasdaq is up 45% YTD, while Pfizer Inc. stock is down 40%. Pfizer's yield is at 14-year highs, nearly 30% undervalued. The collapse
Safeguard your portfolio with these three bargain stocks
06:30am, Tuesday, 21'st Nov 2023
Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents.
Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth
07:54pm, Monday, 20'th Nov 2023
While it's always important to consider passive-income providers, they often lack an underlying growth impetus, which subsequently makes the concept of high-yield dividend growth stocks so compelling.
Texas AG sues Pfizer over quality-control lapses in kids' ADHD drug
07:29pm, Monday, 20'th Nov 2023
Texas Attorney General Ken Paxton accused Pfizer and its supplier Tris Pharma of providing children's ADHD medicine that it knew might be ineffective to the state's Medicaid insurance program for low-
Medicare's exclusion of weight-loss drug coverage under fire
12:26pm, Monday, 20'th Nov 2023
Medicare's decades-old exclusion of weight-loss drug coverage is coming under scrutiny amid mounting evidence that Wegovy and similar medications have health benefits that extend well beyond shedding
2 overlooked stocks that crushed earnings but traded lower
06:22am, Monday, 20'th Nov 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings sea
The 7 Most Undervalued Sleeper Stocks to Buy Now: November 2023
06:15pm, Sunday, 19'th Nov 2023
With investors on the hunt for hot deals, undervalued sleeper stocks are seeing a good deal of attention. In fact, of the ones highlighted below, each carries low risk, and the potential for high retu
Final Trades: Marathon Petroleum, Coca-Cola, Retail, Pfizer
06:32pm, Friday, 17'th Nov 2023
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Pfizer Stock: Cheap But Will Remain Cheap, For Now
01:16pm, Friday, 17'th Nov 2023
When I saw Pfizer Inc. stock settling below pre-pandemic levels, I knew the deterioration of investor sentiment has a lot to do with declining Covid vaccine sales. This was expected. A deep dive into
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
10:31am, Friday, 17'th Nov 2023
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer's (PFE) New Products May Drive Long-Term Sales Growth
09:46am, Thursday, 16'th Nov 2023
Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.
